Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.32 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9308132 | 0.78 | CA1 (0.44) | ZDHHC7 | |
| SCHEMBL9308125 | 0.78 | CA1 (0.44) | ZDHHC7 | |
| SCHEMBL21998571 | 0.75 | MCL1 (0.31) | MME | |
| SCHEMBL7278292 | 0.72 | CTSS (0.41) | MME | |
| SCHEMBL7278294 | 0.72 | CTSS (0.41) | MME | |
| SCHEMBL16382140 | 0.72 | GGT1 (0.41) | MMETGFBR1CYP2C9CYP2C19 | |
| SCHEMBL3070180 | 0.71 | KMT2A (0.39) | CYP3A4CYP2C9CYP2C19MEN1KMT2A | |
| SCHEMBL8245351 | 0.70 | TGFBR1 (0.41) | MMETGFBR1CYP2C9CYP2C19MEN1 | |
| SCHEMBL2503547 | 0.70 | FOLH1 (0.44) | MMECYP2C9CYP2C19 | |
| SCHEMBL13079149 | 0.70 | EPHX1 (0.60) | ZDHHC20ZDHHC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270721-A1 | EP4 receptor agonist, compositions and methods thereof | HAN YONGXIN | 2006-11-30 | — | — | US | disclosed |
| US-7109223-B2 | Oxazolidin-2-one and thiazolidin-2-one derivatives for use as EP4 receptor agonists in the treatment of glaucoma | MERCK & CO. INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060154899-A1 | Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma | MERCK FROSST CANADA LTD. (CA) | 2006-07-13 | — | — | US | disclosed |
| EP-1545517-A1 | OXAZOLIDIN-2-ONE AND THIAZOLIDIN-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF GLAUCOMA | Merck Frosst Canada & Co. (CA) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004019938-A1 | OXAZOLIDIN-2-ONE AND THIAZOLIDIN-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF GLAUCOMA | MERCK FROSST CANADA & CO. (CA) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270721-A1 | EP4 receptor agonist, compositions and methods thereof | PTGER4, PTGER1, PTGER3 | MME 668/4885GBA1 1542/4885ZDHHC20 1673/4885 |
| US-20060154899-A1 | Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma | PTGER4, PTGER1, PTGER2 | MME 1351/4885GBA1 2242/4885ZDHHC20 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.